Health CarePharmaceuticals & Biotechnology
  • Price (USD)224.09
  • Today's Change-9.45 / -4.05%
  • Shares traded4.00
  • 1 Year change+56.12%
  • Beta0.2439
Data delayed at least 15 minutes, as of Jun 11 2021 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.

  • Revenue in USD (TTM)25.49bn
  • Net income in USD6.09bn
  • Incorporated1901
  • Employees35.00k
  • Location
    Eli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
  • Phone+1 (317) 276-2000
  • Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LLY:NYQ since
Disarm Therapeutics IncAnnounced15 Oct 202015 Oct 2020Announced50.94%1.36bn
Data delayed at least 15 minutes, as of Jun 11 2021 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Amgen, Inc.25.16bn7.09bn139.48bn24.30k20.1014.9613.125.5412.0812.0842.9116.220.40521.595.341,035,556.0011.4111.2014.2413.3675.6280.7028.1633.201.349.450.777944.508.833.25-7.370.91970.46715.16
Bristol-Myers Squibb Co42.81bn-6.22bn150.36bn30.25k--4.0032.903.51-2.78-2.7818.8816.860.35424.175.951,415,207.00-5.132.55-6.053.1976.6672.44-14.485.971.45--0.5513192.9562.6220.75-362.14---1.693.99
Merck & Co., Inc.48.02bn7.03bn193.12bn74.00k27.577.1717.914.022.772.7718.9310.640.54642.535.85648,891.908.027.2611.219.4767.6869.5614.6814.950.7779--0.536285.462.463.97-29.059.7329.566.62
AbbVie Inc50.20bn5.08bn203.86bn48.00k40.7614.8615.334.062.832.8328.787.760.41546.896.291,067,979.004.287.735.359.7264.8673.8110.2918.070.72925.190.861797.1537.6914.91-41.90-2.408.4518.50
Eli Lilly And Co25.49bn6.09bn214.91bn35.00k33.5631.1528.688.436.686.6827.947.190.57961.824.76728,160.0013.8610.2819.2514.5475.8877.1923.9119.521.10233.320.695456.069.954.2233.5520.794.538.16
Pfizer Inc.46.41bn9.40bn224.75bn78.50k24.063.2715.804.841.671.978.3212.270.28550.49334.70591,172.005.804.817.155.9622.4378.9520.3417.451.16--0.3657100.531.79-3.02-33.570.109213.286.30
Data as of Jun 11 2021. Currency figures normalised to Eli Lilly and Co's reporting currency: US Dollar USD

Institutional shareholders

35.73%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202165.66m6.85%
PNC Bank, NA (Investment Management)as of 31 Mar 202151.60m5.38%
BlackRock Fund Advisorsas of 31 Mar 202137.80m3.94%
PRIMECAP Management Co.as of 31 Mar 202135.38m3.69%
SSgA Funds Management, Inc.as of 31 Mar 202132.51m3.39%
Wellington Management Co. LLPas of 31 Mar 202131.79m3.32%
Fidelity Management & Research Co. LLCas of 31 Mar 202128.52m2.97%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 202126.16m2.73%
State Farm Investment Management Corp.as of 31 Mar 202118.62m1.94%
Capital Research & Management Co. (World Investors)as of 31 Mar 202114.60m1.52%
More ▼
Data from 31 Mar 2021 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.